On National Latinx AIDS Awareness Day, experts outline HIV prevention gaps in Hispanic communities and how payers can ease PrEP access.
News|Articles|October 13, 2025
Prescription Access Crisis: 40% of GLP-1 RA Rx Are Unfilled
Author(s)Maggie L. Shaw
Fact checked by: Skylar Jeremias
A recent study reveals significant barriers to GLP-1 RA access for diabetes and obesity patients, highlighting racial disparities and high costs.
Advertisement
Advertisement
An alarming 40% of orders for glucagon-like peptide-1 receptor agonists (GLP-1RAs) went unfilled between January 2018 and September 2022, according to a new study from the University of Colorado Health (UCHealth) system, with patients citing soaring costs, insurance roadblocks, and potential prejudicial prescribing behavior because of race as access barriers.1 In addition, despite a higher prevalence of
Related to this article
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase 2 AZUR-1 results.
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Nearly 3 in 4 bariatric surgery candidates had clinical obesity, a phenotype that BMI alone did not distinguish from preclinical obesity.
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
A review of 47 endometriosis guidelines found most came from high-income settings and diverged on biomarkers, repeat surgery, and fertility referral.
Advertisement
Advertisement